Clinical trials: General Movement Assessment
- Condition General Movement Assessment
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Parkinson's Disease
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
- Trial name
- ANDANTE (NCT01049984)
- Testing
- Rasagiline
- Where
- 58 sites in United States
- Volunteers
- 328 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinsonian Syndromes
A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
Patients come to their doctor showing possible symptoms of a movement disorder. It is possible that these symptoms may get worse over time. There is more than one disease that can cause such symptoms.
- Trial name
- NCT00382967
- Testing
- DaTSCAN SPECT imaging
- Where
- 2 sites in United States, France
- Volunteers
- 273 people
- Sponsor
- GE Healthcare
Parkinson's Disease
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Primary Objectives: Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's…
- Trial name
- MOVES-PD (NCT02906020)
- Testing
- venglustat GZ/SAR402671
- Where
- 52 sites in United States, Austria and 14 more
- Volunteers
- 273 people
- Sponsor
- Genzyme, a Sanofi Company